Abeona Therapeutics Inc vs Moody's Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Moody's Corporation trades at $476.73 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 195.9× Abeona Therapeutics Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MCO | |
|---|---|---|
Market Cap | $421.19M | $82.52B |
Sector | Health | Financials |
52-Week High | $7.45 | $539.61 |
52-Week Low | $4.17 | $412.23 |
Enterprise Value | $276.10M | $88.54B |
Dividend Yield | — | 0.86% |
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →